COMP <GO>
ASTH vs MA // EV/EBITDA & P/E VALUATION
Astrana Health Inc. (NASDAQ) VS. Mastercard Incorporated (NYSE) • 15-METRIC TALLY: ASTH 3
— MA 9
▲ EV/EBITDA & P/E VALUATION LEADER: ASTH
LAST: $36.62 (-0.14%) • MKT CAP: $1.82B
valuation
27.3x
LAST: $635.70 (+4.16%) • MKT CAP: $556.88B
valuation
29.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASTH VS. MA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASTH | MA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 33.50% | -28.90 | MA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 27.3x | 29.2x | -1.90 | ASTH | /valuation <GO> |
| Free Cash Flow Yield | 5.75% | 3.08% | +2.67 | ASTH | /fcf-yield <GO> |
| Operating Margin | 2.50% | 57.60% | -55.10 | MA | /operating-margins <GO> |
| Net Profit Margin | 0.80% | 45.60% | -44.80 | MA | /net-margins <GO> |
| Revenue Growth (YoY) | 56.40% | 16.40% | +40.00 | ASTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.43% | 0.49% | -0.06 | MA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.54 | 11.17 | -8.63 | MA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | MA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 68.8 | -22.08 | MA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.90 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 63.6x | 31.2x | +32.40 | MA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.82B | $556.88B | -$555.06B | MA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASTH REV | MA REV | ASTH GROSS % | MA GROSS % | ASTH FCF | MA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $32.79B | — | — | $104.5M | $17.16B |
| FY 2024 | $2.03B | $28.17B | — | — | $44.2M | $14.31B |
| FY 2023 | $1.39B | $25.10B | — | — | $68.2M | $10.85B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASTH // BETA —
MA // BETA 0.90